Key Highlights

● Tempus AI will report third quarter 2026 financial results on November 2.

● A Turkish-language report said second-quarter revenue rose about 22% to roughly $382 million.

● In late May, the company released initial results from its multimodal oncology foundation model efforts.

● Reimbursement, genetic testing competition and the pace of data licensing remain the main uncertainties.

Tempus AI (NASDAQ:TEM) is a precision medicine company that combines laboratory testing, a large library of clinical and molecular data, and software tools meant to help physicians and drug developers. With the third-quarter earnings season in full swing, the company announced that it will report its own third-quarter 2026 financial results on November 2, giving the market its next detailed look at a business that has been growing quickly while still working toward consistent earnings.

The scheduling notice, posted on the company's news page, arrives after a busy several months of product news, including early results from a multimodal foundation model project in cancer, an upgrade to the company's physician platform that adds agent-based features, and a research collaboration with a blood cancer patient organization.

When Will Tempus AI (TEM) Report and What Did It Say?

The company's announcement states that Tempus will report its third quarter 2026 financial results on November 2. Companies typically pair such a notice with the time of a conference call and instructions for accessing a webcast.

The date places Tempus slightly later than many large technology names but within the heart of the reporting season for healthcare and software companies. The report will cover the quarter ended in September and is expected to include revenue by business line, gross margin, operating expenses, cash flow and any change to the company's expectations for the full year.

A scheduling notice contains no results, so nothing in it signals how the quarter went. Anyone interpreting the date as a hint about performance would be reading too much into a routine disclosure. The useful context comes from the prior report, from recent business developments and from the structure of the company's operations, which the following sections review.

How Did Tempus AI (TEM) Perform in the Second Quarter?

A Turkish-language market report said the company's second-quarter revenue rose about 22% to roughly $382 million and that the annual expectation was updated.

Growth of that magnitude for a company of this size reflects expansion in two areas. The genomics business, which includes hereditary and oncology testing, has increased volumes, helped by the earlier acquisition of Ambry Genetics. The data and services business, which licenses de-identified clinical and molecular information to pharmaceutical companies, has added contracts with large drug developers.

The more difficult measure is earnings. Like many young technology and diagnostics companies, Tempus has reported net losses while building scale, and management has talked about steps toward an adjusted measure of operating earnings that excludes certain costs. Differences between adjusted and standard accounting measures will matter in the third-quarter report.

It is also worth remembering that a rate of growth in the low 20% range is a deceleration or acceleration only relative to earlier quarters, which the available sources do not give in full. Acquisitions can inflate year-over-year comparisons until they are included in both periods.

What Did the Multimodal Foundation Model Announcement Reveal About Tempus AI (TEM)?

A Business Wire release dated in late May announced initial results from Tempus's multimodal foundation model efforts for scalable insight generation in oncology. A foundation model is a large AI system trained on varied inputs; in Tempus's case, the idea is to combine genomic sequences, pathology images, clinical notes and treatment outcomes, so that one model can support many questions.

The company has an unusual asset for such work in its library of linked clinical and molecular records, built through its testing network and partnerships with health systems. The argument is that such data allows models to find patterns across cancer types that single-purpose tools would miss, such as which patients are likely to respond to particular therapies.

As with any early-stage research announcement, the findings are preliminary. Results presented in a press release have not necessarily been peer reviewed, and moving from a model to a validated clinical product requires studies, regulatory review in some cases, and acceptance by physicians. The announcement is best seen as a progress marker rather than evidence of revenue.

Why Does the Smart Physician Platform Upgrade Matter for Tempus AI (TEM)?

Another company announcement described an upgrade of the company's physician platform, called Hub, with next-generation agent capabilities. Hub is the interface through which oncologists and other clinicians order tests, view results and access decision support, making it a natural place to introduce AI assistants that summarize records or surface relevant trials.

Embedding agents in a platform physicians already use has a commercial logic. Each additional feature increases the chance that a clinician orders more tests through Tempus instead of a competitor, and it creates data that can improve the company's models. The strategy mirrors approaches in other industries where a software layer drives volume for a core service.

The challenge is trust. Clinicians are cautious about AI outputs that affect patient care, and hospitals have governance processes for new tools. Adoption tends to be gradual, and success depends on demonstrating accuracy and saving time.

The physician platform also serves as a distribution channel for new tests and for clinical trial matching, which ties it to the data business. If agent features make it easier for oncologists to find an eligible study for a patient, the company can earn fees from trial sponsors while giving patients more options, a loop management describes as central to its model.

How Does the Ambry Genetics Business Support Tempus AI (TEM)?

Tempus acquired Ambry Genetics, a hereditary testing laboratory, to broaden its reach beyond tumor sequencing into inherited conditions. A company announcement notes that an Ambry program for identifying patients with a higher likelihood of hereditary cancer was validated for accuracy, an example of the lab's contribution to the company's clinical evidence.

Hereditary testing is a high-volume area with steady demand, in part because guidelines have broadened which patients are eligible. It also produces data that links inherited variants to outcomes. However, it is competitive, with several large laboratories vying for referrals from physicians, and reimbursement from insurers can change.

For the company, integrating Ambry means aligning laboratory operations, billing systems and sales teams, tasks that can create temporary friction. Management has said the combination broadens the data it can license and the services it can offer, but the pace at which those benefits show up in margins is something the upcoming report may help clarify.

What Role Does Data Licensing Play for Tempus AI (TEM)?

The data business is central to the company's pitch. Pharmaceutical firms pay to access de-identified records and, in some cases, to run studies on them or to find patients for clinical trials. Contracts can be multiyear and large, which makes revenue lumpy and makes disclosures about remaining contract value closely watched.

A company announcement described a collaboration with Blood Cancer United to develop a new resource for research. Partnerships with patient organizations extend the company's reach into less common cancers and can supply patient-reported data that complements the lab-based information.

Data licensing also brings scrutiny over privacy and consent. The company says its data is de-identified and handled under health privacy law, and regulators and lawmakers have shown rising interest in how health data is used by commercial firms. Any change in rules could affect what can be shared and how quickly deals are signed.

Large pharmaceutical customers also tend to consolidate vendors over time. A company that wins a flagship agreement can expand to other programs within the same drugmaker, but a loss or a delay in renewal can leave a visible gap, which explains why remaining contract value is a metric that market participants ask about on calls.

What Do the Study and Validation Updates Add for Tempus AI (TEM)?

The company also announced a new study in JCO Precision Oncology validating the company's PURIST test, a gene-expression classifier used in pancreatic cancer. Publication in a peer-reviewed journal is meaningful because physicians and insurers look for such evidence before using a test widely or paying for it.

The company has built a pattern of pairing product launches with publications and conference presentations. The approach reflects the economics of diagnostics: coverage decisions often depend on published validation, and each new coverage decision can unlock a pool of eligible patients.

Still, clinical validation is slow and costly, and not every test achieves broad coverage. Market participants will look to the next report for updates on test volumes, average prices per test and any new reimbursement decisions, since small changes in those variables can move results noticeably.

How Does Competition Shape the Tempus AI (TEM) Landscape?

Tempus competes with large genomic testing laboratories, hospital-based sequencing programs, and companies offering AI tools for pathology and radiology. In data licensing it competes with health data aggregators and with the research arms of large health systems.

Its differentiator is the combination of lab, data and software under one roof, which lets it offer drug developers an end-to-end service from patient identification to trial analytics. Rivals argue that specialized focus matters more, and some large technology companies are expanding in healthcare AI with significant resources.

The competitive landscape also includes regulators. Diagnostics tests and software that influence care can fall under oversight from the Food and Drug Administration, and rule changes could add costs or lengthen timelines. The company has obtained clearances for some products, which helps credibility, but each new tool faces its own review path.

Which Challenges Frame the Tempus AI (TEM) Earnings Report?

Three themes stand out. The first is the path to consistent earnings, since expectations for growth are high and the company has not yet posted steady net earnings. The second is cash management; the business has funded expansion through capital markets and borrowing, so changes in cash use or financing terms will be watched.

The third is reimbursement. Diagnostics revenue depends on payment rates set by government programs and private insurers, and changes can arrive with little notice. A shift in coverage for a major test would show up quickly in results.

On the positive side, the company has reported strong growth, an expanding product line and a well-regarded data asset. Whether that combination translates into steadier earnings is what the November report can begin to show, though a single quarter rarely settles the question.

What Should Readers Look for in the Tempus AI (TEM) Release and Call?

Start with the revenue split. Tempus reports genomics and data and services separately, and the balance between them says a lot about the business. Genomics is steadier and tied to test volumes; data and services can swing with the timing of large contracts. A strong quarter in one line and a soft quarter in the other would tell a different story from balanced growth.

Next, check gross margin and operating expenses. The company has spent heavily on research, sales and the integration of acquisitions, and the pace of spending relative to revenue shows whether operating leverage is emerging. Management commentary on hiring, laboratory automation and the use of AI to lower the cost of each test will give context.

Finally, listen for guidance. The company updated its annual expectation after the second quarter, according to the Turkish-language report, and a further change would be informative. Wall Street research desks typically compare any updated range with their own estimates.